Therapy
152 tracked therapy entities, ordered by how much was published about each in the last 30 days. 265 papers across 111 of them.
- Doxorubicin 9 papers
- Rituximab 8 papers
- Nivolumab 7 papers
- Semaglutide 7 papers
- Pembrolizumab 6 papers
- Bevacizumab 5 papers
- Cisplatin 5 papers
- Deep brain stimulation 5 papers
- HPV vaccine 5 papers
- Immunotherapy 5 papers
- Influenza vaccine 5 papers
- Metformin 5 papers
- Oxaliplatin 5 papers
- Tirzepatide 5 papers
- Cabotegravir 4 papers
- COVID-19 vaccine 4 papers
- Dexamethasone 4 papers
- Dupilumab 4 papers
- Glucagon-like peptide-1 agonist 4 papers
- Neoadjuvant chemotherapy 4 papers
- Paclitaxel 4 papers
- Anti-PD-L1 3 papers
- CAR-T cells 3 papers
- Checkpoint inhibitor 3 papers
- Fluorouracil 3 papers
- Gemcitabine 3 papers
- HPV vaccination 3 papers
- Influenza vaccination 3 papers
- Liver transplantation 3 papers
- Melatonin 3 papers
- Olaparib 3 papers
- Photobiomodulation 3 papers
- Photothermal therapy 3 papers
- Proprotein convertase subtilisin/kexin type 9 inhibitors 3 papers
- Radiation therapy 3 papers
- Robot-assisted radical prostatectomy 3 papers
- Tocilizumab 3 papers
- Tyrosine-kinase inhibitor 3 papers
- Upadacitinib 3 papers
- Vitamin D 3 papers
- Adalimumab 2 papers
- Adjuvant chemotherapy 2 papers
- Antibody-drug conjugate 2 papers
- Atezolizumab 2 papers
- Belimumab 2 papers
- Botulinum toxin type A 2 papers
- Camrelizumab 2 papers
- Celecoxib 2 papers
- Cognitive behavioral therapy 2 papers
- Combination therapy 2 papers
- Continuous positive airway pressure 2 papers
- Dapagliflozin 2 papers
- Infliximab 2 papers
- Methotrexate 2 papers
- Monoclonal antibody 2 papers
- Nirsevimab 2 papers
- Ocrelizumab 2 papers
- PARP inhibitor 2 papers
- Propranolol 2 papers
- Proton therapy 2 papers
- Recombinant zoster vaccine 2 papers
- Resmetirom 2 papers
- Simvastatin 2 papers
- Sorafenib 2 papers
- Stereotactic radiosurgery 2 papers
- Trastuzumab 2 papers
- Venetoclax 2 papers
- [177Lu]Lu-PSMA-617 1 paper
- Abemaciclib 1 paper
- Aflibercept 1 paper
- Anti-PD-1 therapy 1 paper
- Antiseizure Medication 1 paper
- Bispecific antibodies 1 paper
- Blinatumomab 1 paper
- Bortezomib 1 paper
- Capecitabine 1 paper
- Carboplatin 1 paper
- Ceftazidime-avibactam 1 paper
- Celastrol 1 paper
- Cyclin-dependent kinase 4/6 inhibitors 1 paper
- Cyclophosphamide 1 paper
- Docetaxel 1 paper
- Dolutegravir 1 paper
- Donepezil 1 paper
- Doxycycline 1 paper
- Electroacupuncture 1 paper
- Enfortumab vedotin 1 paper
- Gene therapy 1 paper
- Glucocorticoid 1 paper
- Ibuprofen 1 paper
- Imatinib 1 paper
- Ipilimumab 1 paper
- Janus kinase inhibitors 1 paper
- Lenvatinib 1 paper
- Levodopa 1 paper
- Lidocaine 1 paper
- Liraglutide 1 paper
- Niraparib 1 paper
- Osimertinib 1 paper
- Platinum 1 paper
- Pneumococcal conjugate vaccine 1 paper
- Propofol 1 paper
- Proteolysis-targeting chimeras 1 paper
- RNA vaccine 1 paper
- Sirolimus 1 paper
- Sunitinib 1 paper
- Tislelizumab 1 paper
- Tofacitinib 1 paper
- Ustekinumab 1 paper
- Vancomycin 1 paper
- Vorinostat 1 paper
- (S)-(−)-colchicine
- Antimicrobial
- Aspirin
- Atorvastatin
- Automated Insulin Delivery
- Cabozantinib
- Caelyx
- Cetuximab
- Chemoimmunotherapy
- Chemoradiotherapy
- Ciprofloxacin
- Cisplatin/fluorouracil
- Daratumumab
- Dasatinib
- Direct oral anticoagulants
- Durvalumab
- Empagliflozin
- Fenofibrate
- Finerenone
- Gefitinib
- Histone deacetylase inhibitors
- Ibrutinib
- Immunization
- Insulin Therapy
- Lenalidomide
- Meropenem
- Mesalazine
- PD-1/PD-L1 blockade
- Platelet-rich plasma
- Quadrivalent HPV vaccination
- Ranibizumab
- Romosozumab
- Rutin
- Ruxolitinib
- Sodium glucose cotransporter-2 (SGLT2) inhibitors
- Statin
- Tacrolimus
- Tamoxifen
- Taxane
- Temozolomide
- Trametinib